CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
[HTML][HTML] CAR-T cell therapy in large B cell lymphoma
Large B-cell lymphomas (LBCLs) are among the most frequent (about 30%) non-Hodgkin's
lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients …
lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients …
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL
Conflict of interest: COI declared-see note COI notes: DWS, AJ, and RDM are named
inventors on patents for the use of gene expression to subtypes aggressive B-cell …
inventors on patents for the use of gene expression to subtypes aggressive B-cell …
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
AK Miyahira, SC Kamran, T Jamaspishvili… - The …, 2024 - Wiley Online Library
Abstract Introduction The 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting,
themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the …
themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the …
PD‐L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B‐cell lymphoma microenvironment impact CD19 CAR‐T cell …
AV Hirayama, JH Wright, KS Smythe, S Fiorenza… - …, 2024 - Wiley Online Library
CD19‐targeted chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has transformed
the management of relapsed/refractory large B‐cell lymphoma (LBCL), yet durable …
the management of relapsed/refractory large B‐cell lymphoma (LBCL), yet durable …
The Role of Tumor Microenvironment in T Cell Redirecting Therapies of Large B Cell Lymphoma: Translating Lessons Learned from CAR-T to Bispecific Antibodies
KV Lepik, VV Markelov - 2024 - preprints.org
T-cell redirecting therapies, which include chimeric antigen receptor T-cells (CAR-T) and
bispecific antibodies (BSAs), have revolutionized the treatment of relapsed\refractory large B …
bispecific antibodies (BSAs), have revolutionized the treatment of relapsed\refractory large B …
[引用][C] What Is Dark Zone Lymphoma and Is It Clinically Relevant?
B Collinge, DW Scott - Clinical Lymphoma Myeloma and Leukemia, 2024 - Elsevier